Kalvista Pharmaceuticals Inc (KALV)
Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
News
KalVista Pharmaceuticals Evolving HAE Treatment with Real-World Data and Innovations
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sebetralstat by KalVista Pharmaceuticals: A Game-Changer in Hereditary Angioedema Treatment
The company published operating loss of $-25.883 millions, in the most recent fiscal period
Business expenses were on the rise at the company in the fiscal second quarter of 2023
Among many entities, the disclosed also the fourth quarter of 2022 results